Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2014

Collaboration Agreements

Schedule of Collaboration Agreements

Summarized financial information related to our collaboration agreements is presented below:

		Year ended December 31,										As of December 31,1
		Research and Development Expense
		Upfront Fees		Milestones		Extension of Agreements		Amortization of Prepaid Research and Development		Additional Equity Investments Made		Intangible Asset Balance		Equity Investment Balance		Percentage of Outstanding Equity
Acceleron	2014	$	—	$	—	$	—	$	—	$	52.4	$	—	$	179.7	14	%
	2013	—		17.0		—		—		10.0		—		127.2		11	%
	2012	—		—		—		—		—
	2011 and prior	70.0		27.5		—		—		30.5
Acetylon	2014	—		—		—		15.3		—		20.4		25.0		10	%
	2013	50.0		—		—		4.3		10.0		35.7		25.0		10	%
	2012	—		—		—		—		5.0
	2011	—		—		—		—		10.0
Agios	2014	—		—		20.0		—		38.3		—		587.4		14	%
	2013	—		—		20.0		—		12.8		—		113.0		15	%
	2012	—		—		—		—		—
	2011 and prior	121.2		—		20.0		—		37.5
bluebird	2014	—		—		—		0.1		—		0.1		—		N/A
	2013	74.7		—		—		—		—		0.2		—		N/A
Epizyme	2014	—		—		—		—		9.9		—		69.3		11	%
	2013	—		25.0		—		—		1.0		—		69.4		12	%
	2012	65.0		—		—		—		25.0
FORMA	2014	225.0		—		—		0.1		—		0.1		—		N/A
	2013	52.8		—		—		—		—		0.2		—		N/A
MorphoSys	2014	—		—		—		—		—		—		73.9		3	%
	2013	94.3		—		—		—		61.3		—		61.4		3	%
NantBioScience2	2014	50.0		—		—		—		90.0		—		90.0		14	%
OncoMed	2014	2.5		—		—		—		—		—		32.0		5	%
	2013	155.0		—		—		—		22.2		—		43.4		5	%
Sutro	2014	72.6		—		—		0.2		11.9		12.8		17.6		15	%
	2013	—		—		—		2.1		1.7		2.5		5.7		6	%
	2012	26.3		—		—		0.2		4.0
Other Collaboration Arrangements	2014	103.5		8.3		—		7.5		55.7		34.4		58.8		N/A
	2013	149.0		1.0		—		0.9		10.4		23.1		6.1		N/A
	2012	87.2		5.4		—		—		6.5

¹ Year-end balance and percentage of outstanding equity are presented for the current and prior year.

²$25.0 million of expense related to the settlement of contingent matching contributions was also recognized at the inception of the collaboration agreement with NantBioScience and included in Selling, General and Administrative expense.